• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Moderna Set to Join S&P 500

    7/15/21 7:01:00 PM ET
    $SPGI
    $ALXN
    $AZN
    $MRNA
    Finance: Consumer Services
    Finance
    Major Pharmaceuticals
    Health Care
    Get the next $SPGI alert in real time by email

    NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    July 21, 2021

    S&P 500

    Addition

    Moderna

    MRNA

    Health Care



    S&P 500

    Deletion

    Alexion Pharmaceuticals

    ALXN

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    index_services@spglobal.com

    Media Inquiries

    spdji.comms@spglobal.com

    Cision View original content:https://www.prnewswire.com/news-releases/moderna-set-to-join-sp-500-301335329.html

    SOURCE S&P Dow Jones Indices

    Get the next $SPGI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SPGI
    $ALXN
    $AZN
    $MRNA

    CompanyDatePrice TargetRatingAnalyst
    Moderna Inc.
    $MRNA
    12/12/2025$30.00Hold
    Jefferies
    AstraZeneca PLC
    $AZN
    10/27/2025Buy
    Jefferies
    AstraZeneca PLC
    $AZN
    10/16/2025Hold → Sell
    Deutsche Bank
    S&P Global Inc.
    $SPGI
    10/1/2025$540.00Buy
    Seaport Research Partners
    AstraZeneca PLC
    $AZN
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    S&P Global Inc.
    $SPGI
    4/10/2025$600.00Buy
    BofA Securities
    Moderna Inc.
    $MRNA
    3/13/2025$40.00Neutral
    Citigroup
    S&P Global Inc.
    $SPGI
    3/12/2025$599.00Outperform
    Mizuho
    More analyst ratings

    $SPGI
    $ALXN
    $AZN
    $MRNA
    SEC Filings

    View All

    SEC Form 144 filed by Moderna Inc.

    144 - Moderna, Inc. (0001682852) (Subject)

    12/11/25 4:30:43 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    S&P Global Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - S&P Global Inc. (0000064040) (Filer)

    12/4/25 4:16:26 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    12/4/25 1:48:33 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Moderna with a new price target

    Jefferies initiated coverage of Moderna with a rating of Hold and set a new price target of $30.00

    12/12/25 8:52:58 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies resumed coverage on AstraZeneca

    Jefferies resumed coverage of AstraZeneca with a rating of Buy

    10/27/25 8:41:53 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca downgraded by Deutsche Bank

    Deutsche Bank downgraded AstraZeneca from Hold to Sell

    10/16/25 8:19:10 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hussain Abbas sold $13,910 worth of shares (504 units at $27.60), decreasing direct ownership by 25% to 1,515 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    12/11/25 4:16:32 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Mock James M converted options into 47,190 shares and covered exercise/tax liability with 22,817 shares, increasing direct ownership by 129% to 43,200 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    12/8/25 4:44:18 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 22,817 shares and converted options into 47,190 shares, increasing direct ownership by 84% to 53,231 units (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    12/8/25 4:40:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Bancel Stephane bought $5,004,318 worth of shares (160,314 units at $31.22) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:27:16 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Sagan Paul bought $1,004,251 worth of shares (31,620 units at $31.76) (SEC Form 4)

    4 - Moderna, Inc. (0001682852) (Issuer)

    3/4/25 4:24:36 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    KBW Announces Index Rebalancing for Fourth-Quarter 2025

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2025. This quarter, there are constituent changes within six of our indexes: KBW Nasdaq Insurance Index (Index Ticker: KIX), KBW Nasdaq Regional Banking Index (Index Ticker: KRX, ETF Ticker: KBWR), KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY), KBW Nasdaq Property and Casualty Ins

    12/12/25 8:30:00 PM ET
    $AAT
    $ACIW
    $AJG
    Real Estate Investment Trusts
    Real Estate
    Computer Software: Prepackaged Software
    Technology

    Corebridge Financial Set to Join S&P MidCap 400

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Corebridge Financial Inc. (NYSE:CRBG) will replace Allete Inc. (NYSE:ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 17, 2025 S&P MidCap 400 Addition Corebridge Financial CRBG Financials Dec 17, 2025 S&P MidCap 400 Deletion Allete ALE Utilities ABOUT S&P DOW JONES INDICES S

    12/12/25 5:51:00 PM ET
    $ALE
    $CRBG
    $SPGI
    Power Generation
    Utilities
    Life Insurance
    Finance

    Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance

    Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 12, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Scientists developed an antibody treatment that reawakens the immune system to attack pancreatic tumors by blocking sugar-coated disguises cancer cells use to evade detection[1]. Researchers also engineered an off-the-shelf immunotherapy that consistently slowed tumor growth across multiple preclinical pancreatic cancer models while maintaining potency in harsh tumor environments[2]. These advances position Oncolytics Biotech Inc. (NASDAQ:ONCY), Immuneering Corporation (NASDAQ:IMRX), Tango Therapeutics, Inc. (NASDAQ:TNGX), Moderna, Inc. (NASDAQ:MRNA), and Royalty Pharma

    12/12/25 10:47:00 AM ET
    $IMRX
    $MRNA
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SPGI
    $ALXN
    $AZN
    $MRNA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 30, 2020 - Coronavirus (COVID-19) Update: FDA Announces Advisory Committee Meeting to Discuss Second COVID-19 Vaccine Candidate

    For Immediate Release: November 30, 2020 The U.S. Food and Drug Administration has scheduled a meeting of its Vaccines and Related Biological Products Advisory Committee (VRBPAC) on Dec. 17 to discuss the request for emergency use authorization (EUA) for a COVID-19 vaccine from Moderna, Inc. “In keeping with the FDA’s commitment to ensuring full transparency, dialogue and efficiency, the Vaccines and Related Biological Products Advisory Comm

    11/30/20 5:12:14 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Leadership Updates

    Live Leadership Updates

    View All

    Corebridge Financial Set to Join S&P MidCap 400

    NEW YORK, Dec. 12, 2025 /PRNewswire/ -- Corebridge Financial Inc. (NYSE:CRBG) will replace Allete Inc. (NYSE:ALE) in the S&P MidCap 400 effective prior to the open of trading on Wednesday, December 17. Canada Pension Plan Investment Board and Global Infrastructure Partners are acquiring Allete in a deal expected to close soon, pending final closing conditions. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 17, 2025 S&P MidCap 400 Addition Corebridge Financial CRBG Financials Dec 17, 2025 S&P MidCap 400 Deletion Allete ALE Utilities ABOUT S&P DOW JONES INDICES S

    12/12/25 5:51:00 PM ET
    $ALE
    $CRBG
    $SPGI
    Power Generation
    Utilities
    Life Insurance
    Finance

    Ares Management Set to Join S&P 500; Sezzle and Vital Farms to Join S&P SmallCap 600

    NEW YORK, Dec. 8, 2025 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500 and S&P SmallCap 600:  Ares Management (NYSE:ARES) will replace Kellanova (NYSE:K) in the S&P 500 effective prior to the open of trading on Thursday, December 11. Mars Inc. is acquiring Kellanova in a deal expected to close soon, pending final closing conditions.Vital Farms Inc. (NASD: VITL) will replace Heidrick & Struggles Intl Inc. (NASD: HSII) in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, December 11. Advent International and Corvex Private Equity are acquiring Heidrick & Struggles Intl in a deal expected to be completed soon, pending final closing

    12/8/25 5:57:00 PM ET
    $ARES
    $CRGY
    $HSII
    Investment Managers
    Finance
    Oil & Gas Production
    Energy

    CRH, Carvana and Comfort Systems USA Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space.  Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025  S&P 500 Addition CRH CRH Mat

    12/5/25 5:49:00 PM ET
    $ASIX
    $BAH
    $BWA
    Major Chemicals
    Industrials
    Professional Services
    Consumer Discretionary

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    4/10/24 2:03:52 PM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by S&P Global Inc. (Amendment)

    SC 13G/A - S&P Global Inc. (0000064040) (Subject)

    2/13/24 5:13:53 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    SEC Form SC 13G/A filed by Moderna Inc. (Amendment)

    SC 13G/A - Moderna, Inc. (0001682852) (Subject)

    2/7/24 8:42:56 AM ET
    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SPGI
    $ALXN
    $AZN
    $MRNA
    Financials

    Live finance-specific insights

    View All

    KBW Announces Index Rebalancing for Fourth-Quarter 2025

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Keefe, Bruyette & Woods, Inc., a leading specialist investment bank to the financial services and fintech sectors, and a wholly owned subsidiary of Stifel Financial Corp. (NYSE:SF), announces the upcoming index rebalancing for the fourth quarter of 2025. This quarter, there are constituent changes within six of our indexes: KBW Nasdaq Insurance Index (Index Ticker: KIX), KBW Nasdaq Regional Banking Index (Index Ticker: KRX, ETF Ticker: KBWR), KBW Nasdaq Financial Sector Dividend Yield Index (Index Ticker: KDX, ETF Ticker: KBWD), KBW Nasdaq Premium Yield Equity REIT Index (Index Ticker: KYX, ETF Ticker: KBWY), KBW Nasdaq Property and Casualty Ins

    12/12/25 8:30:00 PM ET
    $AAT
    $ACIW
    $AJG
    Real Estate Investment Trusts
    Real Estate
    Computer Software: Prepackaged Software
    Technology

    Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

    Submission based on positive BaxHTN Phase III trial results which demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with resistant or uncontrolled hypertension If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization AstraZeneca's New Drug Application (NDA) for baxdrostat has been accepted for Priority Review by the US Food and Drug Administration (FDA) in the US for the treatment of adult patients with hard-to-control (uncontrolled or treatment resistant) hypertension as an add-on to other antihypertensive medicines when these do not provide adequate lowering of blood pres

    12/2/25 9:18:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    S&P Global Completes $1.8 Billion Acquisition of With Intelligence, Strengthening its Position as a Leader in Private Markets Data & Analytics

    Combination unlocks new market opportunities and cements S&P Global as one of the most comprehensive providers of private markets intelligence NEW YORK, Nov. 25, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the successful completion of its acquisition of With Intelligence, a leading source of private markets data, insights and analytics for $1.8 billion, from a group led by majority investor Motive Partners, a private investment firm focused exclusively on financial and tech-enabled business services companies. First announced in October, the deal significantly

    11/25/25 1:25:00 PM ET
    $SPGI
    Finance: Consumer Services
    Finance